Ambrisentan 1267 5-a]pyrimidinescaffold of dorsomorphin: the discovery

5-a]pyrimidinescaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selectiveMLPCN probe

where it appears to block movement of Arp2 and Arp3 into their active conformation

PubMed Central PMCID: PMC3328245

LC3-mHTT-IN-1

Ambrisentan 1267 5-a]pyrimidinescaffold of dorsomorphin: the discoveryAmbrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by